Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CGEM 
Cullinan Oncology LLC (CGEM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/17/2025: CGEM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0.32% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 438.85M USD | Price to earnings Ratio - | 1Y Target Price 32.44 |
Price to earnings Ratio - | 1Y Target Price 32.44 | ||
Volume (30-day avg) 436431 | Beta -0.11 | 52 Weeks Range 7.27 - 30.19 | Updated Date 04/2/2025 |
52 Weeks Range 7.27 - 30.19 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.78 |
Earnings Date
Report Date 2025-03-12 | When Before Market | Estimate -0.7423 | Actual -0.73 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.26% | Return on Equity (TTM) -32.1% |
Valuation
Trailing PE - | Forward PE 6.3 | Enterprise Value 42020195 | Price to Sales(TTM) 26.88 |
Enterprise Value 42020195 | Price to Sales(TTM) 26.88 | ||
Enterprise Value to Revenue 11.55 | Enterprise Value to EBITDA -1.46 | Shares Outstanding 58512800 | Shares Floating 38980660 |
Shares Outstanding 58512800 | Shares Floating 38980660 | ||
Percent Insiders 4.97 | Percent Institutions 119.02 |
Analyst Ratings
Rating 4.8 | Target Price 33 | Buy 2 | Strong Buy 8 |
Buy 2 | Strong Buy 8 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cullinan Oncology LLC
Company Overview
History and Background
Cullinan Oncology, Inc. is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies. Founded in 2016, it went public in January 2021. The company's approach involves acquiring and developing novel oncology assets.
Core Business Areas
- Drug Development: Focuses on developing targeted therapies for various cancers, including solid tumors and hematological malignancies.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Research and Innovation: Engages in research to identify and acquire promising oncology assets.
Leadership and Structure
The leadership team consists of experienced executives in the biotechnology and pharmaceutical industries. The organizational structure is typical of a clinical-stage biopharmaceutical company.
Top Products and Market Share
Key Offerings
- CLN-081 (formerly TAS6417): An EGFR inhibitor for non-small cell lung cancer (NSCLC) patients harboring EGFR exon 20 insertion mutations. Market share is nascent, as the drug is in development. Competitors include TAK-788 (Mobocertinib), Amivantamab, and other EGFR inhibitors.
- CLN-619: A MICA/B-targeted antibody-drug conjugate (ADC) designed to enhance immunogenic cell death. Market share is minimal as it is still in clinical trials. Competitors include other ADC developers like Seagen and Immunogen, and immune-oncology therapies.
- CLN-978: A novel CD19/CD3 bispecific T-cell engager designed for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) and relapsed/refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL). Market share is zero at this point. Competitors includes other bispecific antibodies and CAR T-cell therapies.
Market Dynamics
Industry Overview
The oncology market is large and growing, driven by an aging population and advances in cancer diagnostics and treatment. It is highly competitive, with many companies developing novel therapies.
Positioning
Cullinan Oncology focuses on targeted therapies and immunotherapies, aiming to address unmet needs in specific cancer subtypes. Competitive advantages include its diversified pipeline and experienced management team.
Total Addressable Market (TAM)
The global oncology market is expected to reach hundreds of billions of dollars. Cullinan Oncology is positioned to capture a share of this market by developing therapies for specific cancer subtypes.
Upturn SWOT Analysis
Strengths
- Diversified pipeline of oncology assets
- Experienced management team
- Focus on targeted therapies
- Strong research and development capabilities
Weaknesses
- Limited revenue due to development stage
- Reliance on successful clinical trials
- Cash burn rate
- Susceptibility to clinical trial failures
Opportunities
- Successful clinical trial results leading to drug approvals
- Partnerships with larger pharmaceutical companies
- Expansion of the pipeline through acquisitions
- Advancements in cancer diagnostics and treatment
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Patent expirations
Competitors and Market Share
Key Competitors
- TAK (TAK)
- JNJ (JNJ)
- MRTX (MRTX)
- BMY (BMY)
- AMGN (AMGN)
Competitive Landscape
Cullinan Oncology faces competition from larger pharmaceutical companies with greater resources and established products. Its advantage lies in its focus on specific cancer subtypes and novel therapeutic approaches.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by pipeline expansion and clinical trial progress.
Future Projections: Future projections depend on the success of clinical trials and regulatory approvals. Analyst estimates vary based on perceived risk and potential market opportunity.
Recent Initiatives: Recent initiatives include advancing drug candidates through clinical trials, presenting data at scientific conferences, and exploring potential partnerships.
Summary
Cullinan Oncology is a clinical-stage biopharmaceutical company with a diversified pipeline. Success hinges on favorable clinical trial outcomes and regulatory approvals. The company's cash position is crucial for funding ongoing research and development efforts. The company is a high-risk, high-reward investment as are all pre-revenue biotech firms.
Similar Companies
AMGN
Amgen Inc
AMGN
Amgen Inc
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
TAK
Takeda Pharmaceutical Co Ltd ADR
TAK
Takeda Pharmaceutical Co Ltd ADR
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports (where available)
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made in consultation with a qualified financial advisor. Market share figures are approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cullinan Oncology LLC
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2021-01-08 | President, CEO & Director Mr. Nadim Ahmed | ||
Sector Healthcare | Industry Biotechnology | Full time employees 111 | Website https://cullinantherapeutics.com |
Full time employees 111 | Website https://cullinantherapeutics.com | ||
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.